Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2000
11/30/2000CA2373748A1 Use of chimeric mutational vectors to change endogenous nucleotide sequences in solid tissues
11/30/2000CA2373693A1 Seven transmembrane receptor genes
11/30/2000CA2373588A1 Gene therapy of pulmonary disease
11/30/2000CA2371828A1 Isolated nucleic acids of the p-hyde family, p-hyde proteins, and methods of inducing susceptibility to induction of cell death in cancer
11/30/2000CA2366408A1 Inhibition of histone deacetylase
11/29/2000EP1054997A1 Method for developing a pharmaceutical active ingredient
11/29/2000EP1054995A1 GABAB-R2a, A 7TM RECEPTOR
11/29/2000EP1054991A1 Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
11/29/2000EP1054988A1 Anti-viral vectors
11/29/2000EP1054980A1 HUMAN HEPARANASE POLYPEPTIDE AND cDNA
11/29/2000EP1054979A1 Compositions and methods for sensitizing and inhibiting growth of human tumor cells
11/29/2000EP1054969A2 Retinoblastoma protein complexes and retinoblastoma interacting proteins
11/29/2000EP1054968A1 Apoptosis inducing molecule ii and methods of use
11/29/2000EP1054963A1 Sequences of an ih ionic channel and the use thereof
11/29/2000EP1054955A2 Compositions comprising viruses and methods for concentrating virus preparations
11/29/2000EP1054950A2 Hiv chemokines
11/29/2000EP1054900A1 Therapeutic uses of keratinocyte growth factor-2
11/29/2000EP1054894A1 Breast cancer resistance protein (bcrp) and the dna which encodes it
11/29/2000EP1054694A2 Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
11/29/2000EP1054683A1 Modified heat shock protein-antigenic peptide complex
11/29/2000EP1054595A1 Methods and compounds for the genetic treatment of hyperlipidemia
11/29/2000EP0862453A4 Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis
11/29/2000CN1275164A Neisseria lactoferrin binding protein
11/29/2000CN1275131A Human lysophospholipase gene (CBFBLH05)
11/29/2000CN1058993C Prepn. and use of molecular chimera for treatment of cancer
11/28/2000US6153598 Acts as synthetic vector for achieving efficient transfection of associated nucleic acid into a cell; gene therapy
11/28/2000US6153597 For gene therapy such as in vitro, ex vivo and/or in vivo transfer of genetic material
11/28/2000US6153596 Polycationic oligomers
11/28/2000US6153595 Composition and method for treatment of CMV infections
11/28/2000US6153436 Transferring nucleotide sequences to target cells in vitro; for utilization as expression vectors for gene therapy
11/28/2000US6153435 Nucleotide sequences coding hybrid envelope polypetides; for gene therapy
11/28/2000US6153434 Substances are delivered into cells using cationic lipid compounds having a disulfide bond which can be complexed with dna to be inserted into a cell in gene therapy; once inside the cell, enzymes cleave disulfide bond and dna is released
11/28/2000US6153433 Suppressing microorganismal propagation; insertion of nucleotide sequences coding viricidal polypeptide into cells infected with hepatitis viral agent, monitor for propagation
11/28/2000US6153427 Erythropoietin-inducible, erythroid-specific DNA construct
11/28/2000US6153391 Contacting p53 and oncoprotein with a peptide fragment or analogue including a defined amino acid sequence or an organic molecule having three-dimensional structure of that amino acid sequence; interferes with binding
11/28/2000US6153382 Viral growth inhibition
11/28/2000US6153200 Administering an isolated and purified bacterial dnajp1 peptide having the amino acid sequence
11/28/2000US6153184 Contacting, by ductal cannulation, the ductal epithelium of the exocrine gland with a cytolytic virus to destroy less than all of the ductal epithelium so as to inhibit formation of cancer of ductal epithelial origin
11/28/2000US6153129 Production scale method of forming microparticles
11/28/2000CA2307357A1 Wbpp and method for assay of wbpp
11/23/2000WO2000070341A2 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
11/23/2000WO2000070099A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000WO2000070092A1 Expression of ets-domain proteins in cancer
11/23/2000WO2000070091A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN PROTEIN KINASE C-δ EXPRESSION
11/23/2000WO2000070087A1 Automated nucleic acid compaction device
11/23/2000WO2000070086A1 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms
11/23/2000WO2000070076A1 Tm4sf receptors
11/23/2000WO2000070075A1 STREPTOCOCCUS PNEUMONIAE yerS
11/23/2000WO2000070071A1 Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
11/23/2000WO2000070070A1 Paramyxoviridae virus vector defective in envelope gene
11/23/2000WO2000070051A1 NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
11/23/2000WO2000070047A2 Full-length molecules expressed in human tissues
11/23/2000WO2000070046A2 Secreted polypeptides and corresponding polynucleotides
11/23/2000WO2000070045A1 Ox2 receptor homologs
11/23/2000WO2000070042A1 143 human secreted proteins
11/23/2000WO2000070036A2 Genes expressed in hippocampus
11/23/2000WO2000070028A1 Sphingosine kinase enzyme
11/23/2000WO2000070024A2 Infectious retroviruses from a leukemic dog cell line with extensive homologies to murine leukemia viruses
11/23/2000WO2000069913A1 EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
11/23/2000WO2000069905A1 LAWSONIA DERIVED GENE AND RELATED OmpH POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES
11/23/2000WO2000069898A2 Molecular interactions in allergy cells
11/23/2000WO2000069897A2 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
11/23/2000WO2000069896A2 Molecular interactions in haematopoietic cells
11/23/2000WO2000069884A2 Compositions isolated from skin cells and methods for their use
11/23/2000WO2000069879A2 Ca7 cg04 gene
11/23/2000WO2000069873A1 Trmd
11/23/2000WO2000069463A1 Compositions and methods for treating cell proliferation disorders
11/23/2000WO2000069455A2 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
11/23/2000WO2000069454A1 Suppression of endogenous igfbp-2 to inhibit cancer
11/23/2000WO2000069443A1 ysxC
11/23/2000WO2000069257A2 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/23/2000WO2000069255A1 Anti-inflammatory therapy for inflammatory mediated infection
11/23/2000WO2000040711A8 Polycystic kidney disease gene homologs required for male mating behavior in nematodes and assays based thereon
11/23/2000WO2000040615A3 EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
11/23/2000WO2000038706A3 Methods for treating cancer and for mediating chemotaxis of dendritic cells
11/23/2000WO2000037685A9 Method of identifying a psychotropic agent using differential gene expression
11/23/2000WO2000037608A3 Micromonospora echinospora genes encoding for biosynthesis of calicheamicin and self-resistance thereto
11/23/2000WO2000034500A3 Methods for increasing the efficiency of gene transfer
11/23/2000WO2000032267A3 Device for locally delivering a drug in a body cavity
11/23/2000WO2000032221A3 Promotion or inhibition of angiogenesis and cardiovascularization
11/23/2000WO2000031262A3 Human neurotensin subtype 2 receptor
11/23/2000WO2000028031A3 Mitogenic regulators
11/23/2000WO2000028020A3 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
11/23/2000WO2000028013A3 Gene expression modulated by activation of microglia or macrophages
11/23/2000WO2000028011A3 Fk506-based regulation of biological events
11/23/2000WO2000023100A3 Genes and proteins predictive and therapeutic for renal disease and associated disorders
11/23/2000WO2000021575A3 Calpain inhibitors and their applications
11/23/2000WO2000020450A3 Calcium channel alpha-2/delta gene
11/23/2000WO2000019978A3 Compositions and methods for enhancing receptor-mediated cellular internalization
11/23/2000WO2000015790A3 Leptin induced genes
11/23/2000WO2000015666A3 Compositions and methods for the treatment of tumors
11/23/2000WO2000012740A3 Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
11/23/2000WO2000012127A3 Dna cancer vaccine and methods for its use
11/23/2000WO1999004775A3 Method of treating dopaminergic and gaba-nergic disorders
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2374045A1 Compositions isolated from skin cells and methods for their use
11/23/2000CA2373938A1 Compositions and methods for treating cell proliferation disorders
11/23/2000CA2373824A1 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
11/23/2000CA2373616A1 Tm4sf receptors
11/23/2000CA2373243A1 Automated nucleic acid compaction device
1 ... 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 ... 870